Healthcare Industry News: Biogen
News Release - June 29, 2007
Biogen Idec Announces Management Change
CAMBRIDGE, Mass.--(HSMN NewsFeed)--Biogen Idec (NASDAQ: BIIB ) announced today that Peter Kellogg, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to become CFO at Merck & Co., Inc."I want to thank Peter for his seven years of distinguished service to the organization," stated James C. Mullen, Biogen Idec's President and Chief Executive Officer. "Peter is a world-class financial executive who helped Biogen Idec grow our core therapeutic areas, execute several significant deals, and expand our global footprint. We wish him all the best with his new assignment at Merck."
Mr. Kellogg will leave Biogen Idec on August 10. The Company will announce its plans regarding the CFO position over the next several weeks.
About Biogen Idec
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.Biogenidec.com.
Source: Biogen Idec
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!